Neurolens
- Industry
- Health Products
- Founded Year
- 2012
- Headquarters
- Coppell, Texas, United States
- Employee Count
- 174
Key People
- Davis Corley - Co-Founder & CEO
- Mark Kremer - Chief Revenue Officer
- Pierre Bertrand - CEO
- Danny Perales - Chief Operating Officer
- Aric Plumley - Chief Technical Officer
- Brant Southwell - VP - Marketing
- Kaelin Currie - VP - Operations
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and business operations.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: Neurolens addresses a significant unmet need in vision care by alleviating symptoms associated with eye misalignment.
By targeting prevalent issues like headaches and eyestrain, Neurolens meets a critical demand in the vision care sector.
- Competition
-
Aspect: First mover
Summary: Neurolens is pioneering the use of contoured prism technology in prescription lenses.
While leading innovation, the company must invest significantly in market education and penetration strategies.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves established principles of optics and neurology, making development challenges manageable.
Leveraging known scientific principles allows for a more straightforward development and refinement process.
- Patent
-
Aspect: Strong
Summary: Neurolens holds patents for its contoured prism technology, providing a competitive edge.
Patents safeguard the unique aspects of the product, deterring competitors and supporting pricing power.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors, supporting its growth initiatives.
With significant capital raised, Neurolens is well-positioned to invest in innovation and scale operations.
- Regulatory
-
Aspect: 510k/PMA
Summary: Neurolens has obtained necessary regulatory approvals for its products.
Achieving regulatory approval demonstrates product safety and efficacy, essential for gaining consumer and practitioner trust.
Opportunity Rollup
- Odds of Success
- 3.3
- Peak Market Share
- 3.9
- Segment CAGR
- 3.2%
- Market Segment
- Ophthalmic Devices
- Market Sub Segment
- Vision Correction Lenses
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.20 |
| 2 | 0.58 |
| 3 | 1.36 |
| 4 | 2.73 |
| 5 | 3.90 |
Key Takeaway
Neurolens, with its innovative contoured prism technology, is well-positioned to address the growing demand for solutions to digital eye strain, supported by a strong team and substantial funding.